"Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond" by Vibeke Strand

Article

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond

RMD Open (2019)

Vibeke Strand, Stanford University
Kurt de Vlam, Katholieke Universiteit Leuven
Jose A Covarrubias-Cobos, Unidad Reumatologica Las Americas S.C.P
Philip J Mease, University of Washington
Dafna D Gladman, Toronto Western Hospital
Linda Chen, Pfizer
Elizabeth Kudlacz, Pfizer
Joseph Wu, Pfizer
Joseph C Cappelleri, Pfizer
Thijs Hendrikx, Pfizer
Ming-Ann Hsu, Pfizer

Link

Disciplines

Publication Date

January 1, 2019

DOI

10.1136/rmdopen-2018-000808

Citation Information

Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, Philip J Mease, et al.. "Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond" RMD Open Vol. 5 Iss. 1 (2019)
Available at: http://works.bepress.com/philip-mease/317/